Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.

ABSTRACT:

Purpose

Infectious complications constitute a leading cause of morbidity and mortality in chronic lymphocytic leukemia (CLL). Patients respond poorly to vaccines, particularly pneumococcal polysaccharide and influenza vaccines. In addition, patients with genetically high-risk disease are at increased risk for early disease progression and death. Lenalidomide, an oral immunomodulatory agent with demonstrated clinical activity in CLL, can potentially restore immune system dysfunction associated with CLL while improving disease outcomes.

Patients and methods

Phase II study randomized 49 patients with genetically high-risk CLL or small lymphocytic lymphoma [SLL; defined as unmutated Ig heavy chain variable region, deletion(17p) or (11q), and/or complex abnormal karyotype], to re

SUBMITTER: Thangavadivel S 

PROVIDER: S-EPMC8166407 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature